Retrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/0 Comments/in Observational, Retrospective studies/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/0 Comments/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/0 Comments/in Observational, Retrospective studies/by MaxThe Role of HSD3B1 in Prostate Cancer Progression and Treatment
/0 Comments/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/0 Comments/in Observational, Post-hoc, Retrospective studies/by MaxEarly PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer
/0 Comments/in Post-hoc, Retrospective studies/by MaxPSA Kinetics Predict Survival Outcomes in High-Volume Metastatic Prostate Cancer
/0 Comments/in Retrospective studies/by MaxTags
abiraterone acetate ADT androgen deprivation therapy antibody-drug conjugate apalutamide ARANOTE artificial intelligence bispecific antibody cancer cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer olaparib oncology personalized medicine preclinical prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery targeted therapy theranostics tumor microenvironment
Latest Posts
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025